• INOVIQ has developed a new cancer treatment using exosomes
• In lab studies, this treatment destroyed 88% of cells from two aggressive cancers: triple negative breast cancer and lung cancer
• The treatment uses engineered immune cell particles called CAR-NK-EVs designed to target and kill cancer cells more precisely

INOVIQ Limited (ASX: IIQ) is pleased to announce a major milestone in its exosome therapeutic program. In recent in vitro studies, INOVIQ's CAR-exosomes demonstrated exceptional efficacy, killing 88% of triple negative breast cancer (TNBC) and lung cancer cells within 96 hours. This marks a major success for INOVIQ's new platform, showing it works well against two solid tumours. The treatment uses engineered immune cell particles called CAR-NK-EVs that are designed to target and kill cancer cells more precisely. INOVIQ uses a special method called EXO-ACE to produce and purify these particles for quality and shelf life. Going forward this could lead to an 'off the shelf' therapy made in advance and used on many patients - unlike other treatments that must be customised. It could be faster to produce, safer to use, and more effective than traditional cell therapies like CAR-T. The treatment will now be tested in mice to see how it works in living systems. Animal studies are the next step before human clinical trials.

INOVIQ's exosome therapeutic platform has now been validated, demonstrating its potential to deliver transformative 'off-the-shelf' therapies. The platform offers potential cost, safety and efficacy advantages over traditional CAR-T cell therapies, enabling development of targeted therapeutics for multiple cancer types.